Platform for Next Generation DNA-based Therapies
Novel & Proprietary oDNA
- Linear closed DNA, just the sequence of interest: oDNA
- Project-based adaptors: “drug-like”
- IP, oDNA for any indication/application
Proprietary GMP Manufacture
- oDNA. Scalable cell-free synthesis
- NVV. Scalable and reproducible production
- Polyplex. Scalable manufacture
Novel & Proprietary NVV
- Polypeptide-based Non-Viral Vectors (NVV)
- Project-based customization:
- Tropism
- Modulation of physchem properties
- IP, NVV to deliver any oDNA
Novel & Proprietary Therapeutic agents
- Polyplex (oDNA & NVV): Therapeutic agent
- Any cargo size
- Re-dosing
- IP, based on project-based polyplex
Our Mission
To provide the next generation of medicines
To treat any genetic disease
- No limit of transgene size
- Re-dosing
- Local & systemic delivery
- Customizable tropism
- Safer DNA
- Storage & Handling requirements
- Scalable GMP production
To open new horizons for current therapeutic approaches
- CAR-Ts
- MAbs
- Vaccines
Our Vision
Non-viral DNA-based Medicines, a novel strategy
to overcome current challenges and achieve the mission
Keystones to Tyris technological platform
